Recent advances in the biomedical applications of fumaric acid and its ester derivatives: The multifaceted alternative therapeutics

Pharmacological Reports

Volumn 68, Issue 2, 2016, Pages 404-414

  Das, Ratul Kumar ^a   Brar, Satinder Kaur ^a   Verma, Mausam ^b  

^a CENTRE EAU TERRE ENVIRONNEMENT   (Canada)

^b CO2 Solutions Inc ^*  (Canada)

Author keywords

Anti cancer; Fumaric acid esters; Immunomodulatory; Tecfidera; Tissue engineering

Indexed keywords

ESTER DERIVATIVE; FUMARIC ACID DERIVATIVE; FUMARIC ACID DIMETHYL ESTER; ESTER; FUMARIC ACID; NEUROPROTECTIVE AGENT;

ALTERNATIVE MEDICINE; ANTINEOPLASTIC ACTIVITY; CARDITIS; CITRIC ACID CYCLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; FUMARIA; FUMARIA OFFICINALIS; HUMAN; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TISSUE ENGINEERING; TISSUE SCAFFOLD; ANIMAL; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

ANIMALS; DIMETHYL FUMARATE; ESTERS; FUMARATES; HUMANS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROPROTECTIVE AGENTS; PSORIASIS;

EID: 84955484984     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/j.pharep.2015.10.007     Document Type: Review

References (114)

1. S.T. Yang, K. Zhang, B. Zhang, and H. Huang Fumaric acid 2nd ed. 2011 Elsevier The Netherlands [Chapter 3]
2. I. Goldberg, J.S. Rokem, and O. Pines Organic acids: old metabolites, new themes J Chem Technol Biotechnol 8 10 2006 1601 1611
3. S.V. Rohokale, S.R. Kote, S.R. Deshmukh, and S.R. Thopate Natural organic acids promoted Beckmann rearrangement: green and expeditious synthesis of amides under solvent-free conditions Chem Pap 68 4 2014 575 578
4. J.S. Temenoff, F.K. Kasper, and A.G. Mikos Topics in tissue engineering 2007 BTE Group
5. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345528.htm [accessed 30.06.15].
6. R. Gniadecki Regulation of keratinocyte proliferation Gen Pharmac 30 5 1998 619 622
7. Y. Cai, C. Fleming, and J. Yan New insights of T cells in the pathogenesis of psoriasis Cell Mol Immunol 9 4 2012 302 308
8. K. Ghoreschi, C. Weigert, and M. Rocken Immunopathogenesis and role of T cells in psoriasis Clin Dermatol 25 6 2007 574 580
9. F.O. Nestle, D.H. Kaplan, and J. Barker Psoriasis Engl J Med 361 5 2009 496 509
10. C.L. Leonardi, A.B. Kimball, K.A. Papp, N. Yeilding, C. Guzzo, Y. Wang, and et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) Lancet 371 9625 2008 1665 1674
11. K. Belge, J. Bruck, and K. Ghoreschi Advances in treating psoriasis F1000Prim Rep 6 4 2014 1 8
12. W. Schweckendiek, and V. Heilung Psoriasis Med Monatsschr 13 2 1959 103 104
13. ® 351
14. U. Mrowietz, and K. Asadullah Dimethylfumarate for psoriasis: more than a dietary curiosity Trends Mol Med 11 1 2005 43 48
15. P.J. Altmeyer, U. Matthes, F. Pawlak, K. Hoffmann, P.J. Frosch, P. Ruppert, and et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients J Am Acad Dermatol 30 6 1994 977 981
16. U. Mrowietz, E. Christophers, and P. Altmeyer Treatment of psoriasis with fumaric acid esters: results of a prospective multicenter study Br J Dermatol 138 3 1998 456 460
17. D.N. Kolbach, and C. Nieboer Fumaric acid therapy in psoriasis. Results and side-effects of 2 years of treatment J Am Acad Dermatol 27 5 1992 769 771
18. H.B.J. Thio, G. van der Schroeff, W.M. Nugteren-Huying, and B.J. Vermeer Long-term systemic therapy with dimethylfumarate and monoethylfumarate (Fumaderm) in psoriasis J Eur Acad Dermatol Venereol 4 1 1995 35 40
19. J.J. Hoefnagel, H.B. Thio, R. Willemze, and J.N. Bouwes Bavinck Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis Brit J Dermatol 149 2 2003 363 369
20. L. Brewer, and S. Rogers Fumaric acid esters in the management of severe psoriasis Clin Exp Dermatol 32 3 2007 246 249
21. K. Reich, D. Thaci, U. Mrowietz, A. Kamps, M. Neureither, and T. Luger Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis - a retrospective study (FUTURE) J Dtsch Dermatol Ges 7 7 2009 603 611
22. E.M. Wain, M.I. Darling, R.D. Pleass, J.N. Barker, and C.H. Smith Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study Br J Dermatol 162 2 2010 427 434
23. M.J. Harries, R.J. Chalmers, and C.E. Griffiths Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases Br J Dermatol 153 3 2005 549 551
24. N. Ismail, P. Collins, S. Rogers, B. Kirby, and A. Lally Drug survival of fumaric acid esters for psoriasis: a retrospective study Br J Dermatol 171 2 2014 397 402
25. H.M. Ockenfels, T. Schultewolter, G. Ockenfels, R. Funk, and M. Goos The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokines and inhibits cytokines of the psoriatic cytokine network Br J Dermatol 139 3 1998 390 395
26. R.d. Jong, A.C. Bezemer, T.P. Zomerdijk, T. van de Pouw-Kraan, T.H. Ottenhoff, and P.H. Nibbering Selective stimulation of T helper 2 cytokine responses by the antipsoriasis agent monomethyl-fumarate Eur J Immunol 26 9 1996 2067 2074
27. N.H.R. Litjens, P.H. Nibbering, A.J. Barrois, T.P.L. Zomerdijk, A.C. Van den Oudenrijn, K.C. Noz, and et al. Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines Br J Dermatol 148 3 2003 444 451
28. B. Sebok, B. Bonnekoh, J. Geijel, and G. Mahrle Antiproliferative and cytotoxic profiles of antipsoriatic fumaric acid derivatives in keratinocyte cultures Eur J Pharmacol 270 1 1994 79 87
29. B. Sebok, B. Bonnekoh, and G. Mahrle IL-1 alpha-induced expression of ICAM-1on cultured hyperproliferative keratinocytes: suppression by antipsoriatic dimethyl-fumarate Int J Dermatol 33 5 1994 367 370
30. W. Stühlinger, M. Innerebner, and W. Aberer The nephrotoxic effect of therapy with fumaric acid esters in psoriasis Dtsch Med Wochenschr 115 45 1990 1712 1715
31. N. Haring, H. Sprenger Mahr, M. Mundle, R. Strohal, and K. Lhotta Early detection of renal damage caused by fumaric acid ester therapy by determination of urinary β2-microglobulin Br J Dermatol 164 3 2011 648 651
32. L. Fliegner, and P. Spiegel Osteomalacia as an apparently rare side effect of oral fumaric acid therapy Secondary DeToni-Debré Fanconi syndrome in the adult Hautarzt 43 9 1992 554 560
33. C. Raschka, and H.J. Koch Long term treatment of psoriasis using fumaric acid preparations can be associated with severe proximal tubular damage Hum Exp Toxicol 18 12 1999 738 739
34. M. Clanet Jean-Martin Charcot. 1825 to 1893 Int MS J 15 2 2008 59 61
35. A. Compston, and A. Coles Multiple sclerosis Lancet 359 9313 2002 1221 1231
36. A. Compston, and A. Coles Multiple sclerosis Lancet 372 9648 2008 1502 1517
37. www.msif.org/global-ms-news [accessed 22.06.15].
38. S. Schimrigk, N. Brune, K. Hellwig, C. Lukas, B. Bellenberg, M. Rieks, and et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study Eur J Neurol 13 6 2006 604 610
39. S. Schilling, S. Goelz, R. Linker, F. Luehder, and R. Gold Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration Clin Exp Immunol 145 1 2006 101 107
40. Anon. BG 12: BG 00012, BG 12/Oral Fumarate, FAG-201, second-generation fumarate derivative - Fumapharm/Biogen Idec Drugs R D 6 4 2005 229 230
41. M. Wakkee, and H.B. Thio Drug evaluation: BG-12, an immunomodulatory dimethylfumarate Curr Opin Invest Drugs 8 11 2007 955 962
42. D. Moharregh-Khiabani, R.A. Linker, R. Gold, and M. Stangel Fumaric acid and its esters: an emerging treatment for multiple sclerosis Curr Neuropharm 7 1 2009 60 64
43. www.biogenidec.com/press-release-details.aspx?ID=14712&M=News&PID=61997&NewsID=1809 [accessed 22.06.15].
44. U. Ermis, J. Weis, and J.B. Schulz PML in a patient treated with fumaric acid N Engl J Med 368 17 2013 1657 1658
45. B.W. van Oosten, J. Killestein, F. Barkhof, C.H. Polman, and M.P. Wattjes PML in a patient treated with dimethyl fumarate from a compounding pharmacy N Engl J Med 368 2013 1658 1659 [Erratum,N Engl J Med 2013;368(17):1950.]
46. T. Rosenkranz, M. Novas, and C. Terborg PML in a patient with lymphocytopenia treated with dimethyl fumarate N Engl J Med 372 15 2015 1476 1478
47. B.O. Khatri, J. Garland, J. Berger, J. Kramer, L. Sershon, T. Olapo, and et al. The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal Leukoencephalopathy risk Mult Scler Relat Disord 4 4 2015 377 379
48. C.M. Spencer, E.C. Crabtree-Hartman, K. Lehmann-Horn, B.A. Cree, and S.S. Zamvil Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate Neurol Neuroimmunol Neuroinflamm 2 3 2015 e76
49. www.fda.gov/Drugs/DrugSafety/ucm424625.htm
50. Z. Xu, F. Zhang, F. Sun, K. Gu, S. Dong, and D. He Dimethyl fumarate for multiple sclerosis Cochr Database Syst Rev 4 2014 10.1002/14651858.CD011076 Art. no.: CD011076
51. www.myocarditisfoundation.org/about-myocarditis/ [accessed 22.06.15].
52. R. Loewe, M. Pillinger, R. de Martin, U. Mrowietz, M. Gröger, W. Holnthoner, and et al. Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-kB-dependent manner J Invest Dermatol 117 6 2011 1363 1368
53. R. Loewe, W. Holnthoner, M. Groger, M. Pillinger, F. Gruber, and D. Mechtcheriakova Dimethylfumarate inhibits TNF-Induced Nuclear Entry of NF-κB/p65 in human endothelial cells J Immunol 168 9 2002 4781 4787
54. M. Milenkovic, N. Arsenovic-Ranin, D. Vucicevic, B. Bufan, I. Jancic, and Z. Stojic-Vukanic Beneficial effects of dimethyl fumarate on experimental autoimmune myocarditis Arch Med Res 39 7 2008 639 646
55. A. Kis, D.M. Yellon, and G.F. Baxter Role of nuclear factor-kappa B activation in acute ischaemia-reperfusion injury in myocardium Br J Pharmacol 138 5 2003 894 900
56. S. Meili-Butz, T. Niermann, E. Fasler-Kan, V. Barbosa, N. Butz, D. John, and et al. Dimethyl fumarate, a small molecule drug for psoriasis, inhibits Nuclear Factor-κB and reduces myocardial infarct size in rats Eur J Pharmacol 586 1-3 2008 251 258
57. S.A. Cross, D.R. Cook, A.W. Chi, P.J. Vance, L.L. Kolson, B.J. Wong, and et al. Dimethyl fumarate, an immune modulator and inducer of the antioxidant response, suppresses HIV replication and macrophage-mediated neurotoxicity: a novel candidate for HIV neuroprotection J Immunol 187 10 2011 5015 5025
58. A.J. Gill, and D.L. Kolson Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy Crit Rev Immunol 33 4 2013 307 359
59. A.J. Gill, C.E. Kovacsics, S.A. Cross, P.J. Vance, L.L. Kolson, K.L. Jordan-Sciutto, and et al. Heme oxygenase-1 deficiency accompanies neuropathogenesis of HIV-associated neurocognitive disorders J Clin Invest 124 10 2014 4459 4472
60. T.J. Schmidt, M. Ak, and U. Mrowietz Reactivity of dimethyl fumarate and methylhydrogen fumarate towards glutathione and N-acetyl-l-cysteine - preparation of S-substituted thiosuccinic acid esters Bioorg Med Chem 15 1 2007 333 342
61. R.A. Linker, D.H. Lee, S. Ryan, A.M. van Dam, R. Conrad, P. Bista, and et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway Brain 134 3 2011 678 692
62. D. Wiesner, I. Merdian, J. Lewerenz, A.C. Ludolph, L. Dupuis, and A. Witting Fumaric acid esters stimulate astrocytic VEGF expression through HIF-1α and Nrf2 PLOS ONE 8 10 2013 e76670
63. K. Zhu, and U. Mrowietz Inhibition of dendritic cell differentiation by fumaric acid esters J Invest Dermatol 116 2 2001 203 208
64. P.H. Nibbering, B. Thio, T.P.L. Zomerdijk, A.C. Bezemer, R.L. Beijersbergen, and R. van Furth Effects of Monomethylfumarate on human granulocytes J Invest Dermatol 101 1 1993 37 42
65. T.J. Stoof, J. Flier, S. Sampat, C. Nieboer, C.P. Tensen, and D.M. Boorsma The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells Br J Dermatol 144 6 2001 1114 1120
66. J. Hanson, A. Gille, and S. Offermanns Role of HCA2 (GPR109A) in nicotinic acid and fumaric acid ester-induced effects on the skin Pharmacol Ther 136 1 2012 1 7
67. A. Heiligenhaus, H. Li, A. Schmitz, S. Wasmuth, and D. Bauer Improvement of herpetic stromal keratitis with fumaric acid derivate is associated with systemic induction of T helper 2 cytokines Clin Exp Immunol 142 1 2005 180 187
68. I. Venten, N. Hess, A. Hirschmüller, P. Altmeyer, and N. Brockmeyer Treatment of therapy-resistant alopecia areata with fumaric acid esters Eur J Med Res 11 7 2006 300 305
69. S. Wang, L. Lu, and M.J. Yaszemski Bone tissue-engineering material poly(propylene fumarate): correlation between molecular weight, chain dimensions, and physical properties Biomacromolecules 7 6 2006 1976 1982
70. A.P.D. Elfick Poly(e-caprolactone) as a potential material for a temporary joint spacer Biomaterials 23 23 2002 4463 4467
71. S.J. Peter, J.A. Nolley, M.S. Widmer, J.E. Merwin, M.J. Yaszemski, A.W. Yasko, and et al. In vivo degradation of a poly(propylene fumarate)/beta-tricalcium phosphate injectable composite scaffold J Biomed Mater Res 41 1 1998 1 7
72. R.A. Horch, N. Shahid, A.S. Mistry, M.D. Timmer, A.G. Mikos, and A.R. Barron Nanoreinforcement of poly(propylene fumarate)-based networks with surface modified alumoxane nanoparticles for bone tissue engineering Biomacromolecules 5 5 2004 1990 1998
73. B. Farshid, G. Lalwani, and B. Sitharaman Cytotoxicity of polypropylene fumarate nanocomposites used in bone tissue engineering 39th annual northeast bioengineering conference 2013 10.1109/NEBEC.2013.73
74. M.E. Christenson, W. Soofi, J.L. Holm, N.R. Cameron, and A.G. Mikos Biodegradable fumarate-based PolyHIPEs as tissue engineering scaffolds Biomacromolecules 8 12 2007 3806 3814
75. K.W. Lee, S. Wang, B.C. Fox, E.L. Ritman, M.J. Yaszemski, and L. Lu Poly(propylene fumarate) bone tissue engineering scaffold fabrication using stereolithography: effects of resin formulations and laser parameters Biomacromolecules 8 4 2007 1077 1084
76. P.X. Lan, J.W. Lee, Y.J. Seol, and D.W. Cho Development of 3D PPF/DEF scaffolds using micro-stereolithography and surface modification J Mater Sci: Mater Med 20 1 2009 271 279
77. J.P. Fisher, D. Dean, and A.G. Mikos Photocrosslinking characteristics and mechanical properties of diethyl fumarate/poly(propylene fumarate) biomaterials Biomaterials 23 22 2002 4333 4343
78. A.J. Domb, N. Manor, and O. Elmalak Biodegradable bone cement compositions based on acrylate and epoxide terminated poly(propylene fumarate) oligomers and calcium salt compositions Biomaterials 17 4 1996 411 417
79. C.H. Chang, T.C. Liao, Y.M. Hsu, H.W. Fang, C.C. Chen, and F.H. Lin A poly(propylene fumarate) - calcium phosphate based angiogenic injectable bone cement for femoral head osteonecrosis Biomaterials 31 14 2010 4048 4055
80. L. Cai, K. Wang, and S. Wang Poly(ethylene glycol)-grafted poly(propylene fumarate) networks and parabolic dependence of MC3T3 cell behavior on the network composition Biomaterials 31 16 2010 4457 4466
81. M.D. Timmer, C. Carter, C.G. Ambrose, and A.G. Mikos Fabrication of poly(propylene fumarate)-based orthopedic implants by photo-crosslinking through transparent silicone molds Biomaterials 24 25 2003 4707 4714
82. M.D. Timmer, C.G. Ambrose, and A.G. Mikos In vitro degradation of polymeric networks of poly(propylene fumarate) and the crosslinking macromer poly(propylene fumarate)-diacrylate Biomaterials 24 4 2003 571 577
83. R.G. Payne, J.S. McGonigle, M.J. Yaszemski, A.W. Yasko, and A.G. Mikos Development of an injectable, in situ crosslinkable, degradable polymeric carrier for osteogenic cell populations. Part 2. Viability of encapsulated marrow stromal osteoblasts cultured on crosslinking poly(propylene fumarate) Biomaterials 23 22 2002 4373 4380
84. R.G. Payne, J.S. McGonigle, M.J. Yaszemski, A.W. Yasko, and A.G. Mikos Development of an injectable, in situ crosslinkable, degradable polymeric carrier for osteogenic cell populations. Part 3. Proliferation and differentiation of encapsulated marrow stromal osteoblasts cultured on crosslinking poly(propylene fumarate) Biomaterials 23 22 2002 4381 4387
85. S. He, M.J. Yaszemski, A.W. Yasko, P.S. Engel, and A.G. Mikos Injectable biodegradable polymer composites based on poly(propylene fumarate) crosslinked with poly(ethylene glycol)-dimethacrylate Biomaterials 21 23 2000 2389 2394
86. M. Jayabalan, V. Thomas, and P.N. Rajesh Polypropylene fumarate/phloroglucinol triglycidyl methacrylate blend for use as partially biodegradable orthopaedic cement Biomaterials 22 20 2001 2749 2757
87. E.L. Hedberga, C.K. Shiha, J.J. Lemoinea, M.D. Timmera, M.A.K. Liebschnera, J.A. Jansenb, and et al. In vitro degradation of porous poly(propylene fumarate)/poly(dl-lactic-co-glycolic acid) composite scaffolds Biomaterials 26 16 2005 3215 3225
88. L.J. Suggs, J.L. West, and A.G. Mikos Platelet adhesion on a bioresorbable poly(propylene fumarate-co-ethylene glycol) copolymer Biomaterials 20 7 1999 683 690
89. E.P. Childers, M.O. Wang, M.L. Becker, J.P. Fisher, and D. Dean 3D printing of resorbable poly(propylene fumarate) tissue engineering scaffolds Mat Res Soc Bull 40 2 2015 119 126
90. M.B. Runge, M. Dadsetan, J. Baltrusaitis, A.M. Knight, T. Ruesink, E.A. Lazcano, and et al. The development of electrically conductive polycaprolactone fumarate-polypyrrole composite materials for nerve regeneration Biomaterials 31 23 2010 5916 5926
91. M. Farokhi, S. Sharifi, Y. Shafieyan, Z. Bagher, F. Mottaghitalab, A. Hatampoor, and et al. Porous crosslinked poly(e-caprolactone fumarate)/nanohydroxyapatite composites for bone tissue engineering J Biomed Mater Res A 100 4 2012 1051 1060
92. Y. Shafieyan, S. Sharifi, M. Imani, M.A. Shokrgozar, N. Aboudzadeh, and M.A. Atai Biocompatible composite based on poly(e-caprolactone fumarate) and hydroxyapatite Polym Adv Technol 22 12 2011 2182 2190
93. S. Wang, L. Lu, J.A. Gruetzmacher, B.L. Currier, and M.J. Yaszemski Synthesis and characterizations of biodegradable and crosslinkable poly(e-caprolactone fumarate), poly(ethylene glycol fumarate), and their amphiphilic copolymer Biomaterials 27 6 2006 832 841
94. V. Desai, and M. Kowshik Synthesis and characterization of fumaric acid functionalized AgCl/titania nanocomposite with enhanced antibacterial activity J Nanosci Nanotechnol 13 4 2013 2826 2834
95. H. Ueda, M.C. Hacker, A. Haesslein, S. Jo, D.M. Ammon, R.N. Borazjani, and et al. Injectable, in situ forming poly(propylene fumarate)-based ocular drug delivery systems J Biomed Mater Res A 83 3 2007 656 666
96. N. Shokri, H.A. Java, S. Fouladdel, A. Khalaj, R. Dinarvand, and E. Azizi Preparation and characterization of crosslinked and non-crosslinked polycaprolactone fumarate (PCLF) NPs as carriers for doxorubicin HCl Afr J Pharm Pharmacol 5 7 2011 797 805
97. J. Jansen, M.J. Boerakker, J. Heuts, J. Feijen, and D.W. Grijpma Rapid photo-crosslinking of fumaric acid monoethyl ester-functionalized poly(trimethylene carbonate) oligomers for drug delivery applications J Control Release 147 1 2010 54 61
98. D. Chickering, J. Jacob, and E. Mathiowitz Poly(fumaric-co-sebacic). Microspheres as oral drug delivery systems Biotechnol Bioeng 52 1 1996 96 101
99. U. Mrowietz, E. Christophers, and P. Altmeyer Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use Br J Dermatol 141 3 1999 424 429
100. D. Werdenberg, R. Joshi, S. Wolffram, H.P. Merkle, and P. Langguth Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters Biopharm Drug Dispos 24 6 2003 259 273
101. N.H. Litjens, E. van Strijen, C. van Gulpen, H. Mattie, J.T. van Dissel, H.B. Thio, and et al. In vitro pharmacokinetics of anti-psoriatic fumaric acid esters BMC Pharmacol 4 2004 22
102. N.H.R. Litjens, J. Burggraaf, E.V. Strijen, C.V. Gulpen, H. Mattie, R.C. Schoemaker, and et al. Pharmacokinetics of oral fumarates in healthy subjects Br J Clin Pharm 58 4 2004 429 432
103. M. Rostami-Yazdi, B. Clement, T.J. Schmidt, D. Schinor, and U. Mrowietz Detection of metabolites of fumaric acid esters in human urine: implications for their mode of action J Invest Dermatol 129 1 2009 231 234
104. M. Rostami-Yazdi, B. Clement, and U. Mrowietz Pharmacokinetics of anti-psoriatic fumaric acid esters in psoriasis patients Arch Dermatol Res 302 7 2010 531 538
105. K. Kuroda, M. Akao, M. Kanisawa, and K. Miyaki Inhibitory effect of Capsella bursa pastoris extract on growth of Ehrlich solid tumor in mice Cancer Res 36 6 1976 1900 1903
106. K. Kuroda, and M. Akao Antitumor anti-intoxication activities of fumaric acid in cultured cells Gan 72 5 1981 777 782
107. K. Kuroda, M. Kanisawa, and M. Akao Inhibitory effect of fumaric acid on forestomach and lung carcinogenesis by a 5-nitrofuran naphthyridine derivative in mice J Natl Cancer Inst 69 6 1982 1317 1320
108. K. Kuroda, M. Akao, and K. Terao Fumaric acid enhances DNA synthesis of rat hepatocytes by counteracting the toxicities of mitomycin C and aflatoxin B1 Jpn J Cancer Res 77 8 1986 750 758
109. M. Akao, and K. Kuroda Inhibitory effect of fumaric acid on hepatocarcinogenesis by thioacetamide in mice Chem Pharm Bull (Tokyo) 38 7 1990 2012 2014
110. V.G. Bespalov, V.A. Aleksandrov, A.S. Petrov, and D.N. Troian The anticarcinogenic effects of fumaric acid on models of carcinogenesis in the esophagus, nervous system and kidney, Voprosy Onkologii 38 8 1992 956 961
111. M. Tsubaki, N. Ogawa, T. Takeda, K. Sakamoto, H. Shimaoka, A. Fujita, and et al. Dimethyl fumarate induces apoptosis of hematopoietic tumor cells via inhibition of NF-kB nuclear translocation and down-regulation of Bcl-xL and XIAP Biomed Pharmacother 68 8 2014 999 1005
112. C.A. Roa Engel, A.J.J. Straathof, T.W. Zijlmans, W.M. van Gulik, and L.A.M. van der Wielen Fumaric acid production by fermentation Appl Microbiol Biotechnol 78 3 2008 379 389
113. E. Launert Guide to edible and medicinal plants of Britain and Northern Europe 1989 Hamlyn
114. 4-induced liver damage in rats Pharmacologia 3 1 2012 9 14